Verona Pharma plc

NasdaqGM VRNA

Verona Pharma plc Return on Equity (ROE) for the year ending December 31, 2023: -21.81%

Verona Pharma plc Return on Equity (ROE) is -21.81% for the year ending December 31, 2023, a 26.84% change year over year. Return on equity measures profit against shareholder equity; higher ROE indicates superior profitability and value creation.
  • Verona Pharma plc Return on Equity (ROE) for the year ending December 31, 2022 was -29.81%, a 20.60% change year over year.
  • Verona Pharma plc Return on Equity (ROE) for the year ending December 31, 2021 was -37.55%, a -6.54% change year over year.
  • Verona Pharma plc Return on Equity (ROE) for the year ending December 31, 2020 was -35.24%, a 62.64% change year over year.
  • Verona Pharma plc Return on Equity (ROE) for the year ending December 31, 2019 was -94.32%, a -198.27% change year over year.
Key data
Date Return on Equity (ROE) Return on Capital Employed (ROCE) Interest Coverage Ratio Debt to Equity Ratio
Market news
SV Wall Street
NasdaqGM: VRNA

Verona Pharma plc

CEO Dr. David S. Zaccardelli Pharm.D.
IPO Date April 28, 2017
Location United Kingdom
Headquarters 3 More London Riverside
Employees 79
Sector Healthcare
Industries
Pharmaceuticals Biotechnology Clinical Trials Composite Materials Pollution Treatment
Description

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.

Similar companies

VKTX

Viking Therapeutics, Inc.

USD 33.50

3.49%

MDGL

Madrigal Pharmaceuticals, Inc.

USD 339.97

5.25%

SNDX

Syndax Pharmaceuticals, Inc.

USD 14.65

1.67%

INZY

Inozyme Pharma, Inc.

USD 1.52

11.77%

MREO

Mereo BioPharma Group plc

USD 3.01

2.73%

VTYX

Ventyx Biosciences, Inc.

USD 1.85

0.54%

MLTX

MoonLake Immunotherapeutics

USD 45.99

-2.40%

TERN

Terns Pharmaceuticals, Inc.

USD 4.66

3.10%

AKRO

Akero Therapeutics, Inc.

USD 57.56

2.04%

PTGX

Protagonist Therapeutics, Inc.

USD 38.52

2.50%

APLS

Apellis Pharmaceuticals, Inc.

USD 30.37

5.53%

ABOS

Acumen Pharmaceuticals, Inc.

USD 1.54

4.05%

DAWN

Day One Biopharmaceuticals, Inc.

USD 12.22

0.58%

IDYA

IDEAYA Biosciences, Inc.

USD 25.10

4.11%

AMLX

Amylyx Pharmaceuticals, Inc.

USD 3.69

1.93%

StockViz Staff

February 6, 2025

Any question? Send us an email